Published on October 15, 2009 at 8:01 AM
AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab(TM) formulation of sufentanil will be featured in two oral presentations at the upcoming American Society of Anesthesiologists Annual Meeting in New Orleans.
Dr. Pamela Palmer, Chief Medical Officer of AcelRx, will present in the following sessions. Abstracts are available through the American Society of Anesthesiologists web site.
Tuesday, October 20, 2009 Oral Session - Chronic &
Cancer Pain 8:00 am, Room 355 Abstract 1040 "Pharmacokinetics and Dose Proportionality of Sublingual Sufentanil NanoTab in Healthy Volunteers" Tuesday, October 20, 2009 Oral Session - Regional Anesthesia & Acute Pain 1:00 pm, Room 355 Abstract 1222 "Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers"
SOURCE AcelRx Pharmaceuticals, Inc.